依美斯汀(Emedastine,EME)由日本Kanabo-Kowa公司联合开发,1993年8月首先在日本上市,商品名DAREN,是新的第二代H1受体拮抗剂。依美斯汀可选择性地作用于H1受体,临床用于治疗荨麻疹、湿疹或皮炎、瘙痒症及痒疹、过敏性鼻炎等。本文就其药物作用机制、药代动力学、不良反应及应用前景作一简要介绍。 Emedastine (EME) was jointly developed by Japan’s Kanabo-Kowa Co., Ltd. and was first marketed in Japan in August 1993 under the trade name DAREN. It is a new second generation H1 receptor antagonist. Emamectin selectively acts on H1 receptors and is used clinically to treat urticaria, eczema or dermatitis, pruritus and prurigo, allergic rhinitis, and the like. This article gives a brief introduction of its drug action mechanism, pharmacokinetics, adverse reactions and application prospects.